Research work · 1973

Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia

Tin Han, Ediz Z. Ezdinli, Katsutaro Shimaoka, Dinesh V. Desai

Cancer

Abstract

Eleven patients with chronic lymphocytic leukemia were treated with chlorambucil alone and 15 patients received combined chlorambucil-prednisone therapy in a double-blind study. Mean age, duration of disease, physical findings, and hematologic data in the two groups were essentially comparable. Complete remission was observed in 3 and partial remission in 10 of the patients in the chlorambucil-prednisone treated group; but only one of the patients obtained complete and four showed partial remission with chlorambucil alone. This difference was statistically significant (p < 0.05). Hematologic toxicity was less frequent in the combination group. Two-year survival was 93% for combination group and 54% for chlorambucil-treated group. The difference, however, was not statistically significant. Our data indicate that chlorambucil-prednisone therapy is superior to chlorambucil in the treatment of chronic lymphocytic leukemia.

DOI: 10.1002/1097-0142(197303)31:3<502::aid-cncr2820310303>3.0.co;2-7